792899-38-8

Basic information

• Product Name: PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXY-PHENYL)-AMIDE
• Synonyms: PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXY-PHENYL)-AMIDE;N-(4-isopropoxyphenyl)piperazine-1-carboxamide
• CAS NO: 792899-38-8
• Molecular Formula: C₁₄H₂₁N₃O₂
• Molecular Weight: 263.33544
• Mol File: 792899-38-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 439.239°C at 760 mmHg
• Flash Point: 219.444°C
• Appearance: /
• Density: 1.152g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXY-PHENYL)-AMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXY-PHENYL)-AMIDE(792899-38-8)
• EPA Substance Registry System: PIPERAZINE-1-CARBOXYLIC ACID (4-ISOPROPOXY-PHENYL)-AMIDE(792899-38-8)

Safety Data

• Hazardous Substances Data: 792899-38-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H21N3O2/c1-11(2)19-13-5-3-12(4-6-13)16-7-9-17(10-8-16)14(15)18/h3-6,11H,7-10H2,1-2H3,(H2,15,18)

Upstream product

• 110-85-0 piperazine 
• 948552-60-1 C₁₀H₁₂ClNO₂ 
• 7664-66-6 4-(isopropoxy)aniline 
• 916666-95-0 4-(4-Isopropoxy-phenylcarbamoyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 916610-30-5 (4-isopropoxy-phenyl)-carbamic acid 4-nitro-phenyl ester 

Downstream Products

• 387867-13-2 Tandutinib 

Relevant articles and documents

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib

The synthesis of three substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib (1), erlotinib (2) and gefitinib (3) in improved yields is reported. The intermediates were characterized by NMR and the purities determined by HPLC.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R3, B, Z, r and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.